Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative

NCT03509961 is registered in ClinicalTrials.gov with Pediatric Transplantation & Cellular Therapy Consortium as lead sponsor.

NCT NCT03509961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03509961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2018
Completion date
July 1, 2026
Enrollment
95 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia